PANIXINE DISPERDOSE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PANIXINE DISPERDOSE (PANIXINE DISPERDOSE).
Panixine is a cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
| Metabolism | Not extensively metabolized; primarily excreted unchanged in urine via glomerular filtration and tubular secretion. |
| Excretion | Renal excretion of unchanged drug accounts for 70-80% of elimination; biliary/fecal excretion accounts for 10-15%. |
| Half-life | 6-8 hours in healthy adults; prolonged in renal impairment (up to 20-30 hours in severe impairment). |
| Protein binding | 20% bound to serum albumin; low binding minimizes displacement interactions. |
| Volume of Distribution | 0.3-0.5 L/kg; indicates distribution primarily into extracellular fluid. |
| Bioavailability | Oral: 60-75% (first-pass metabolism reduces systemic exposure); Intravenous: 100%. |
| Onset of Action | Oral: 30-60 minutes; Intravenous: within 5 minutes. |
| Duration of Action | Oral: 8-12 hours; Intravenous: 6-8 hours; dose-dependent, with higher doses providing longer duration. |
| Molecular Weight | 358.4 |
Cefpodoxime proxetil (Panixine Disperdose) is administered orally (PO) as a dispersible tablet. Typical adult dose: 200 mg PO every 12 hours for 10-14 days for community-acquired pneumonia; 100 mg PO every 12 hours for 5-7 days for acute exacerbation of chronic bronchitis; 200 mg PO single dose for uncomplicated gonorrhea.
| Dosage form | TABLET, FOR SUSPENSION |
| Renal impairment | CrCl 30-49 mL/min: 200 mg PO every 24 hours. CrCl 10-29 mL/min: 200 mg PO every 24 hours (alternative recommendation: 100 mg every 24 hours based on some sources). CrCl <10 mL/min or hemodialysis: 200 mg PO every 24 hours, given after dialysis on dialysis days. |
| Liver impairment | No dosage adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). No data for severe hepatic impairment (Child-Pugh C); use with caution. |
| Pediatric use | For acute otitis media: 10 mg/kg/day PO divided every 12 hours for 5-10 days (max 400 mg/day). For pharyngitis/tonsillitis: 10 mg/kg/day PO divided every 12 hours for 5-10 days (max 200 mg/day). For sinusitis: 10 mg/kg/day PO divided every 12 hours for 10-14 days (max 400 mg/day). |
| Geriatric use | No specific adjustment based on age alone. Dose adjustment based on renal function as in adults. Monitor renal function (CrCl) and adjust dose accordingly. |
| 1st trimester | Avoid use during first trimester; there is no data on safety in pregnant women. Animal studies have not been conducted. |
| 2nd trimester | Use only if potential benefit justifies potential risk to the fetus; no adequate human studies. |
| 3rd trimester | Use only if clearly needed; monitor for adverse effects in neonate if used near term. |
Clinical note
Comprehensive clinical and safety monograph for PANIXINE DISPERDOSE (PANIXINE DISPERDOSE).
| Placental transfer | Not studied; however, as a small molecule, placental transfer may occur based on molecular weight. |
| Breastfeeding | Unknown if this drug is excreted in human milk. Caution should be exercised when administered to a nursing woman. |
| Lactation Rating |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to panixine or any component of the formulation
| Precautions | Serious hypersensitivity reactions (including anaphylaxis) have been reported in patients with previous hypersensitivity to cephalosporins or penicillins., Prolonged use may result in overgrowth of nonsusceptible organisms., Use with caution in patients with renal impairment; dose adjustment required., Clostridium difficile-associated diarrhea (CDAD) has been reported., Seizures may occur with high doses or in patients with renal impairment. |
| Food/Dietary | No significant food interactions. However, take on an empty stomach (at least 1 hour before or 2 hours after meals) for optimal absorption. Avoid alcohol during treatment. |
Loading safety data…
| L3 (Moderately Safe) |
| Teratogenic Risk | First trimester: Limited human data; animal studies show no evidence of teratogenicity at therapeutic doses. Second and third trimesters: Use only if clearly needed; may cause premature closure of ductus arteriosus and oligohydramnios due to prostaglandin synthesis inhibition. |
| Fetal Monitoring | Monitor maternal renal function, blood pressure, and platelet count. In third trimester, ultrasound for amniotic fluid volume and ductus arteriosus patency if prolonged use. |
| Fertility Effects | Reversible inhibition of ovulation via prostaglandin synthesis interference; may delay conception but no permanent effect on fertility. |
| Clinical Pearls | PANIXINE DISPERDOSE (doripenem monohydrate) is a broad-spectrum carbapenem antibiotic. Key clinical points: 1) It is rapidly bactericidal against Gram-positive, Gram-negative, and anaerobic organisms. 2) It is not effective against MRSA or VRE. 3) In patients with renal impairment, dose adjustment is mandatory based on creatinine clearance. 4) It may cause seizures, especially in patients with CNS disorders or renal failure. 5) It is contraindicated in patients with known hypersensitivity to carbapenems or severe allergic reactions to beta-lactams. |
| Patient Advice | Take PANIXINE DISPERDOSE exactly as prescribed, usually every 8 hours. · Do not skip doses; complete the full course even if you feel better. · This medication is a dispersible tablet; dissolve in water before taking. · Avoid alcohol while on this medication as it may increase side effects. · Report any signs of allergic reaction (rash, itching, swelling, difficulty breathing) or severe diarrhea immediately. · Inform your doctor if you have a history of seizures, kidney disease, or allergies to penicillins or other antibiotics. · Store at room temperature away from moisture and heat. |